The Seville expert workshop for progress in posttransplant lymphoproliferative disorders.
暂无分享,去创建一个
A. Webster | A. Mehta | J. Chapman | J. Pascual | V. Leblond | A. Rickinson | A. Zuckermann | D. Glotz | H. Hirsch | B. Moulin | R. Trappe | V. Dharnidharka | A. Pagliuca | D. Hanto | T. Gross | F. Russo | M. Castro | M. C. Castro
[1] M. Michaels,et al. Epstein–Barr Virus Infection and Posttransplant Lymphoproliferative Disorder , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[2] C. Printz. Advances in childhood cancers , 2012, Cancer.
[3] W. Klapper,et al. Plasmablastic Posttransplant Lymphoma: Cytogenetic Aberrations and Lack of Epstein-Barr Virus Association Linked With Poor Outcome in the Prospective German Posttransplant Lymphoproliferative Disorder Registry , 2012, Transplantation.
[4] G. Salles,et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. , 2012, The Lancet. Oncology.
[5] Sonali M. Smith,et al. Primary Central Nervous System (PCNS) Post-Transplant Lymphoproliferative Disease (PTLD): An International Report of 65 Cases in the Modern Era , 2011 .
[6] B. Gärtner,et al. Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell post-transplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease: a prospective analysis of 8 cases , 2011, Haematologica.
[7] A. Kirk,et al. Sirolimus Enhances the Magnitude and Quality of Viral‐Specific CD8+ T‐Cell Responses to Vaccinia Virus Vaccination in Rhesus Macaques , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[8] Jie Zheng,et al. Infection and malignancy after pediatric heart transplantation: the role of induction therapy. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[9] Dolca Thomas,et al. An Integrated Safety Profile Analysis of Belatacept in Kidney Transplant Recipients , 2010, Transplantation.
[10] A. Pavie,et al. Adapted Management of EBV Reactivation After Solid Organ Transplantation: An Effective Prevention of Post Transplantation Lymphoproliferative Disorders (PTLD). Results of the Largest Prospective Study on 251 Patients , 2010 .
[11] G. Opelz,et al. Pediatric Kidney Transplantation: Analysis of Donor Age, HLA Match, and Posttransplant Non-Hodgkin Lymphoma: A Collaborative Transplant Study Report , 2010, Transplantation.
[12] K. Mucha,et al. Post-transplant lymphoproliferative disorder in view of the new WHO classification: a more rational approach to a protean disease? , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[13] R. Marcus,et al. Management of post‐transplant lymphoproliferative disorder in adult solid organ transplant recipients – BCSH and BTS Guidelines , 2010, British journal of haematology.
[14] B. McCrindle,et al. Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[15] R. Marcus,et al. Diagnosis of post‐transplant lymphoproliferative disorder in solid organ transplant recipients – BCSH and BTS Guidelines , 2010, British journal of haematology.
[16] M. Gulley,et al. Using Epstein-Barr Viral Load Assays To Diagnose, Monitor, and Prevent Posttransplant Lymphoproliferative Disorder , 2010, Clinical Microbiology Reviews.
[17] G. Opelz,et al. Impact of HLA Mismatching on Incidence of Posttransplant Non-Hodgkin Lymphoma After Kidney Transplantation , 2010, Transplantation.
[18] Scott E. Smith,et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] J. Kaldor,et al. Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study , 2010, BMJ : British Medical Journal.
[20] G. Mazariegos,et al. Chronic high Epstein–Barr viral load carriage in pediatric small bowel transplant recipients , 2009, Pediatric transplantation.
[21] A. Morgans,et al. Posttransplant lymphoproliferative disorder following kidney transplant. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[22] Gerhard Opelz,et al. C3 polymorphisms and allograft outcome in renal transplantation. , 2009, The New England journal of medicine.
[23] M. Kojima,et al. Age‐related EBV‐associated B‐cell lymphoproliferative disorders: Diagnostic approach to a newly recognized clinicopathological entity , 2009, Pathology international.
[24] J. Preiksaitis,et al. Epstein‐Barr Virus and Posttransplant Lymphoproliferative Disorder in Solid Organ Transplant Recipients , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[25] G. Opelz,et al. Epidemiology of Pretransplant EBV and CMV Serostatus in Relation to Posttransplant Non-Hodgkin Lymphoma , 2009, Transplantation.
[26] W. Irish,et al. Epidemiologic critique of literature on post‐transplant neoplasms in solid organ transplantation , 2009, Clinical transplantation.
[27] T. Larson,et al. Posttransplant Lymphoproliferative Disorder Following Pancreas Transplantation , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[28] J. Kaldor,et al. Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation. , 2009, Blood.
[29] C. Macedo,et al. The Impact of EBV Load on T-Cell Immunity in Pediatric Thoracic Transplant Recipients , 2009, Transplantation.
[30] L. Danziger-Isakov,et al. Hematologic complications of anti‐CMV therapy in solid organ transplant recipients , 2009, Clinical transplantation.
[31] R. Ahmed,et al. mTOR regulates memory CD8 T cell differentiation , 2009, Nature.
[32] S. Webber,et al. Chronic high Epstein‐Barr viral load carriage in pediatric liver transplant recipients , 2009, Pediatric transplantation.
[33] V. Dharnidharka,et al. Post-transplant lymphoproliferative disease , 2009, Pediatric Nephrology.
[34] M. Ho,et al. Timing of Epstein-Barr Virus Acquisition and the Course of Posttransplantation Lymphoproliferative Disorder in Children , 2009, Transplantation.
[35] S. Gupta,et al. Viral immune monitoring for post‐transplant lymphoproliferative disorder , 2009, Pediatric transplantation.
[36] J. Fishman. Transplantation Microbiology: An Evolving Pillar of Transplant Care , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[37] R. Hetzer,et al. Diagnosis and treatment of post‐transplantation lymphoproliferative disorder in pediatric heart transplant patients , 2009, Pediatric transplantation.
[38] J. Fox,et al. Interlaboratory Comparison of Epstein‐Barr Virus Viral Load Assays , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[39] B. Gärtner,et al. Efficiency of antiviral therapy plus IVIG in a case of primary EBV infection associated PTLD refractory to rituximab, chemotherapy, and antiviral therapy alone , 2009, Annals of Hematology.
[40] H. Chi,et al. Quantitative Epstein-Barr virus viral load monitoring in pediatric liver transplantation. , 2008, Transplantation proceedings.
[41] Joan W. Miller,et al. Long-Term Results of Rabbit Antithymocyte Globulin and Basiliximab Induction , 2008 .
[42] B. Einollahi,et al. Associations of Human Leukocyte Antigen (HLA) haplotypes with risk of developing lymphoproliferative disorders after renal transplantation. , 2007, Annals of transplantation.
[43] A. Kirk,et al. Dissociation of Depletional Induction and Posttransplant Lymphoproliferative Disease in Kidney Recipients Treated With Alemtuzumab , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[44] B. Dörken,et al. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution , 2007, Annals of Hematology.
[45] J. Pascual. Post-transplant lymphoproliferative disorder--the potential of proliferation signal inhibitors. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[46] H. Fickenscher,et al. Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective analysis. , 2007, The Lancet. Oncology.
[47] B. Moulin,et al. Post‐Transplant Lymphoproliferative Disorders Occurring After Renal Transplantation in Adults: Report of 230 Cases From the French Registry , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[48] M. Pavlakis,et al. Retransplantation After Post‐Transplant Lymphoproliferative Disorders: An OPTN/UNOS Database Analysis , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[49] E. González-Barca,et al. Association of Human Leukocyte Antigen Haplotypes with Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation , 2006, Transplantation.
[50] Boris Katz,et al. CMV‐IVIG for Prevention of Epstein Barr Virus Disease and Posttransplant Lymphoproliferative Disease in Pediatric Liver Transplant Recipients , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[51] G. Opelz,et al. Disassociation Between Risk of Graft Loss and Risk of Non-Hodgkin Lymphoma With Induction Agents in Renal Transplant Recipients , 2006, Transplantation.
[52] T. Habermann,et al. Post‐Transplant Lymphoproliferative Disorders Following Liver Transplantation: Incidence, Risk Factors and Survival , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[53] G. Salles,et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. , 2006, Blood.
[54] R. Kotloff,et al. Management of patients with post‐transplant lymphoproliferative disorder: the role of rituximab , 2006, Transplant international : official journal of the European Society for Organ Transplantation.
[55] A. Humar,et al. A Randomized Trial of Ganciclovir versus Ganciclovir Plus Immune Globulin for Prophylaxis Against Epstein-Barr Virus Related Posttransplant Lymphoproliferative Disorder , 2006, Transplantation.
[56] B. Kestenbaum,et al. Risk of Lymphoma after Renal Transplantation Varies with Time: An Analysis of the United States Renal Data System , 2006, Transplantation.
[57] M. Pescovitz,et al. Ganciclovir and Acyclovir Reduce the Risk of Post‐Transplant Lymphoproliferative Disorder in Renal Transplant Recipients , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[58] L. Agodoa,et al. Posttransplant Lymphoproliferative Disorders after Renal Transplantation in the United States in Era of Modern Immunosuppression , 2005, Transplantation.
[59] D. Dunn,et al. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation , 2005, Cancer.
[60] V. Dharnidharka,et al. Risk for post‐transplant lymphoproliferative disorder after polyclonal antibody induction in kidney transplantation , 2005, Pediatric transplantation.
[61] H. Heslop,et al. Quantitative EBV Viral Loads and Immunosuppression Alterations can Decrease PTLD Incidence in Pediatric Liver Transplant Recipients , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[62] S. McDonald,et al. Lymphoproliferative Disease after Renal Transplantation in Australia and New Zealand , 2005, Transplantation.
[63] Epstein–Barr virus and lymphoproliferative disorders after transplantation , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[64] G. Snell,et al. Epstein-Barr Virus Primary Mismatching and HLA Matching: Key Risk Factors for Post Lung Transplant Lymphoproliferative Disease , 2004, Transplantation.
[65] G. Opelz,et al. Lymphomas After Solid Organ Transplantation: A Collaborative Transplant Study Report , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[66] R. Wolfe,et al. Immunosuppression and the Risk of Post‐Transplant Malignancy Among Cadaveric First Kidney Transplant Recipients , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[67] L. Swinnen,et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation1 , 2003, Transplantation.
[68] David W. Johnson,et al. A single-centre experience of post-renal transplant lymphoproliferative disorder , 2003, Transplant international : official journal of the European Society for Organ Transplantation.
[69] V. Shahinian,et al. Epstein-Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoroliferative disorder in adult renal allograft recipients1 , 2003 .
[70] V. Shahinian,et al. Epstein-Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoroliferative disorder in adult renal allograft recipients. , 2003, Transplantation.
[71] V. Dharnidharka,et al. Post‐Transplant Lymphoproliferative Disorder in the United States: Young Caucasian Males are at Highest Risk , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[72] H. Riess,et al. Identification of early antigen BZLF1/ZEBRA protein of Epstein–Barr virus can predict the effectiveness of antiviral treatment in patients with post‐transplant lymphoproliferative disease , 2002, British journal of haematology.
[73] P. Hopkins,et al. Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients. , 2002, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[74] J. Preiksaitis,et al. Epstein-Barr virus infection in transplant recipients: Summary of a workshop on surveillance, prevention and treatment. , 2002, The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses.
[75] D. Stablein,et al. RISK FACTORS FOR POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD) IN PEDIATRIC KIDNEY TRANSPLANTATION: A REPORT OF THE NORTH AMERICAN PEDIATRIC RENAL TRANSPLANT COOPERATIVE STUDY (NAPRTCS)1 , 2001, Transplantation.
[76] Clara D. Bloomfield,et al. The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting--Airlie House, Virginia, November, 1997. , 2000, The hematology journal : the official journal of the European Haematology Association.
[77] G Flandrin,et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[78] R. Busuttil,et al. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. , 1998, Transplantation.
[79] F. Davi,et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[80] J. Reyes,et al. Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[81] A. Kliger,et al. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. , 1997, Transplantation.
[82] N. Harris,et al. Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. , 1997, Seminars in diagnostic pathology.
[83] H. Koeppen,et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. , 1996, Transplantation.
[84] T. Habermann,et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[85] T. Habermann,et al. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. , 1995, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[86] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[87] R. Fisher,et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. , 1990, The New England journal of medicine.
[88] M Tubiana,et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.